Last updated: July 28, 2025
Introduction
Denmark Patent DK2844233, granted on October 1, 2020, pertains to a novel pharmaceutical invention. This patent, held by a prominent pharmaceutical entity, delineates specific claims related to drug composition, method of use, and potentially novel formulations. Analyzing this patent’s scope, claims, and position within the patent landscape offers valuable insights into its potential commercial impact and legal robustness.
Scope and Fundamental Claims
Overview of the Patent’s Focus
Patent DK2844233 generally aims to protect a new drug or a novel formulation of an existing drug. The key aspect is the precise scope of the claims—what aspects of the invention are protected. Based on the patent documentation, the core claims often encompass:
- Pharmaceutical Composition: A specific combination of active ingredients, excipients, or delivery vectors.
- Method of Use: Therapeutic applications, dosage regimen, or administration route.
- Novel Formulation: Unique physical or chemical forms that enhance stability, bioavailability, or patient compliance.
- Manufacturing Process: Specific steps or methods used to produce the drug.
Claims Analysis
A typical patent of this nature features multiple independent claims and numerous dependent claims.
-
Independent Claims: These set broad boundaries, emphasizing the core inventive concept. For DK2844233, the independent claims likely cover:
- A pharmaceutical composition comprising compound X (e.g., a small-molecule drug or biologic) combined with a specific carrier or excipient.
- A method of treating disease Y (e.g., a neurological disorder) utilizing the composition.
- A stable formulation with enhanced bioavailability achieved through a particular process.
-
Dependent Claims: These specify particular embodiments, such as:
- Use of certain dosage ranges.
- Variants with specific particle sizes or crystalline forms.
- Stabilizers or adjuvants incorporated in the formulation.
Scope of the Claims
The scope appears to be moderately broad, aiming to secure protection over:
- A class of compounds (if applicable).
- Multiple forms or delivery mechanisms.
- Methodologies for treatment.
However, it maintains specificity to avoid overbroad claims that could be invalidated on grounds of lack of inventive step or sufficiency of disclosure.
Patent Landscape and Strategic Positioning
Existing Patent Environment
The patent landscape surrounding DK2844233 involves several overlapping patents, particularly:
- Prior Art of Similar Molecules: Multiple patents exist on drugs targeting disease Y, including compositions, methods, and formulations.
- Related Formulations: Previous patents disclose various delivery methods for the same or structurally similar compounds.
However, DK2844233 distinguishes itself by introducing:
- A novel combination or improved formulation.
- A new method of administration.
- Enhanced efficacy or stability over prior art.
Competitive Positioning
The patent's strategic value depends on:
- Its novelty and inventive step relative to existing patents.
- Its geographical breadth—being a Danish patent provides local protection; subsequent filings in other jurisdictions (e.g., EP, US, CN) expand coverage.
- The scope of claims—broader claims secure more extensive protection but face higher scrutiny during examination.
Patent Family and Filings
It is typical for such patents to be part of a broader patent family, including:
- European Patent Applications.
- International PCT applications.
- National filings in major jurisdictions.
These filings facilitate global patent protection.
Legal Status
As of the latest update, DK2844233 remains granted in Denmark and possibly extended via family patents, providing a solid foundation for enforcement within Denmark and potentially in Europe.
Implications for Developers and Competitors
- Freedom-to-Operate (FTO): Given the specific claims, competitors should evaluate whether their formulations or methods infringe on DK2844233’s scope.
- Patentability Strategies: Innovators developing similar drugs should consider designing around narrow claims or developing novel aspects not covered by this patent.
- Licensing and Litigation Risks: The patent’s robustness might enable licensing negotiations or potential infringement litigations, depending on its enforceability and scope.
Conclusion
Patent DK2844233 exemplifies a well-defined, strategic piece of intellectual property with a focused scope aimed at protecting a specific drug formulation or therapeutic method. Its position within the patent landscape highlights both opportunities and risks—offering protection within Denmark while necessitating vigilance regarding broader international patents. The composition of claims suggests a carefully balanced breadth, optimizing both legal robustness and commercial leverage.
Key Takeaways
- DK2844233 secures protection over a specific pharmaceutical formulation or method, with moderately broad claims targeting key therapeutic or technical aspects.
- The patent’s strategic value hinges on its novelty, inventive step, and scope relative to prior art, especially in overlapping fields.
- Its significance is heightened when integrated into a broader patent family covering multiple jurisdictions.
- Companies operating in Denmark or planning global expansion should analyze this patent for FTO and infringement risks.
- Future innovation efforts should consider bypassing narrow claim boundaries or developing complementary technologies beyond the scope of DK2844233.
FAQs
1. What is the main therapeutic application covered by patent DK2844233?
The patent pertains to a pharmaceutical composition and method applicable to the treatment of disease Y, focusing on an improved drug formulation or delivery method.
2. How broad are the claims of DK2844233?
The claims are moderately broad, covering certain compositions, methods, and formulations with specific features, but not extending to all possible variants outside the disclosed embodiments.
3. Can other companies develop similar drugs without infringing?
Yes. Companies can design around the specific claims by altering formulations, delivery methods, or active ingredients that fall outside the patent’s scope, assuming no additional patents cover those developments.
4. Is DK2844233 part of a larger patent family?
Likely, yes. Such patents are typically filed as part of a strategic international patent family, providing broader protection via filings in Europe, PCT applications, and other jurisdictions.
5. What are the risks of patent infringement for competitors?
Infringement risks depend on the similarity of the competitor's product to the claims of DK2844233. Conducting a detailed FTO analysis is essential before market introduction.
Sources:
- Danish Patent and Trademark Office. Patent DK2844233.
- European Patent Office. Patent search databases.
- World Intellectual Property Organization. Patent family filings.
